Is Ocugen Worth Another Look After Good News for COVID Vaccine Covaxin?

·3 min read

The World Health Organization is expected to soon grant emergency use listing for COVID-19 vaccine Covaxin. While the vaccine was developed by Bharat Biotech, Ocugen (NASDAQ: OCGN) has the rights to market Covaxin in the U.S. and in Canada. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Ocugen stock is worthy of another look by investors if Covaxin receives EUL.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting